Are you over 18 and want to see adult content?
More Annotations
![Focus Lab | Moving Organizations Forward through Branding and Interactive Solutions](https://www.archivebay.com/archive/89528e83-eaa4-4ad6-b927-a50935d76105.png)
Focus Lab | Moving Organizations Forward through Branding and Interactive Solutions
Are you over 18 and want to see adult content?
![جميع اوراق لعبة يوغي يو بالعربي](https://www.archivebay.com/archive/1174a0b1-b28e-4d69-8cce-7e4bedb3a31f.png)
جميع اوراق لعبة يوغي يو بالعربي
Are you over 18 and want to see adult content?
![Top Rated Server Administrators and Remote Hands - Servermeister.com](https://www.archivebay.com/archive/df89b0e8-5e2f-4cc3-9f11-fd8180522d58.png)
Top Rated Server Administrators and Remote Hands - Servermeister.com
Are you over 18 and want to see adult content?
![Australia's Independent Online Department Store - Affordable Furniture, Sporting Goods & More!](https://www.archivebay.com/archive/50ec613f-ea75-4569-bede-30573e710a3f.png)
Australia's Independent Online Department Store - Affordable Furniture, Sporting Goods & More!
Are you over 18 and want to see adult content?
![Buiducsang's Weblog | Just another WordPress.com weblog](https://www.archivebay.com/archive/bc5f81e5-332b-4606-b502-273f22b7b939.png)
Buiducsang's Weblog | Just another WordPress.com weblog
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of https://olive-pk.jp](https://www.archivebay.com/archive6/images/7b510dd3-1404-49f8-ba1b-aa2bf02a784e.png)
A complete backup of https://olive-pk.jp
Are you over 18 and want to see adult content?
![A complete backup of https://ladno.ru](https://www.archivebay.com/archive6/images/3954402a-15e3-45bd-a54a-eea22f7ab240.png)
A complete backup of https://ladno.ru
Are you over 18 and want to see adult content?
![A complete backup of https://found.co.uk](https://www.archivebay.com/archive6/images/817d2ea6-b462-4d02-b6a3-7a81b0e82dee.png)
A complete backup of https://found.co.uk
Are you over 18 and want to see adult content?
![A complete backup of https://sheeats.ca](https://www.archivebay.com/archive6/images/afdf48ae-2d84-481a-8cea-3189493dee9a.png)
A complete backup of https://sheeats.ca
Are you over 18 and want to see adult content?
![A complete backup of https://vivenergy.es](https://www.archivebay.com/archive6/images/e19520ab-07da-4461-805f-796a01891568.png)
A complete backup of https://vivenergy.es
Are you over 18 and want to see adult content?
![A complete backup of https://politik.gr](https://www.archivebay.com/archive6/images/85038e6e-d5e2-4641-bec4-9f178c42414c.png)
A complete backup of https://politik.gr
Are you over 18 and want to see adult content?
![A complete backup of https://keviniscooking.com](https://www.archivebay.com/archive6/images/8ee0b33e-79ff-421c-8010-022082ab7d37.png)
A complete backup of https://keviniscooking.com
Are you over 18 and want to see adult content?
![A complete backup of https://be-quadrat.at](https://www.archivebay.com/archive6/images/5f77d6b3-2cd4-46db-ab46-4ccc7c5d7b9a.png)
A complete backup of https://be-quadrat.at
Are you over 18 and want to see adult content?
![A complete backup of https://english-club.tv](https://www.archivebay.com/archive6/images/2bed356b-63ad-4f39-bf77-6a610236794d.png)
A complete backup of https://english-club.tv
Are you over 18 and want to see adult content?
![A complete backup of https://lendico.de](https://www.archivebay.com/archive6/images/3bd242be-c002-480e-8e66-957268db0a8a.png)
A complete backup of https://lendico.de
Are you over 18 and want to see adult content?
![A complete backup of https://wa-shahed.ir](https://www.archivebay.com/archive6/images/bdcedb8e-ad93-4b95-a052-6dd6cb9ad2ab.png)
A complete backup of https://wa-shahed.ir
Are you over 18 and want to see adult content?
![A complete backup of https://elsevier.de](https://www.archivebay.com/archive6/images/9eadfa4a-8e15-4e92-a42c-badae0e849b8.png)
A complete backup of https://elsevier.de
Are you over 18 and want to see adult content?
Text
AICURE
AiCure Support +1(800) 770-1266 | support@aicure.com | Help CenterHelp Center
COMPANY – AICURE
Company. AiCure delivers patient insights to improve clinical trials. As the only company to provide a holistic view of the patient, AiCure directly engages patients via smartphones to deliver meaningful, high-quality data around patient behavior to sponsors and sites. These insights from AiCure’s proprietary AI platform empower sites toLEARN – AICURE
Collaborating with AiCure is a unique opportunity to bring deeper and more novel insights to clinical research without participants ever having to leave the comfort of home. The AiCure platform aligns with our unique product development model that harnesses behavioralOPENDBM – AICURE
AiCure’s OpenDBM is a software package that allows for calculation of digital biomarkers of health and functioning from video or audio of an individual’s behavior. It integrates existing tools for measurement of behavioral characteristics such as facial activity, voice, and movement into a single package for measurement of overallbehavior.
SITE-PERSPECTIVES ON PATIENT ENGAGEMENT: SOLUTIONS FOR Site-Perspectives on Patient Engagement: Solutions for NASH Trials. By Nadege Gunn, MD. Keeping track of patients in clinical trials has always been challenging for sites and sponsors. However, the COVID-19 pandemic has taken the challenge of patient engagement to new levels. Patients with fatty liver disorders such as nonalcoholic DEMYSTIFYING CNS SYMPTOM TRACKING WITH ADVANCED AI Tingling or numbness in the extremities. Weakness. Loss of sight or changes in sight. Memory loss. Changes to cognitive ability. Lack of coordination. These kinds of symptoms typically fluctuate in severity over time. They can also be impacted by factors outside the therapy being studied. For instance, the patient’s level of physicalactivity
USE OF DIGITAL BIOMARKERS IN A PARKINSON’S DISEASE OPEN Open-label extension study to test the safety and efficacy of CVL-751 Use of digital biomarkers in a Parkinson’s Disease open-label extension study for frequent and objective assessment of AICURE ANNOUNCES NEW STUDY RESULTS DEMONSTRATING 90% AiCure announces new study results demonstrating 90% adherence from Phase 2 Abbvie study. New York, Sept. 26, 2016 — AiCure, a clinically-validated artificial intelligence company that visually confirms medication ingestion on smartphones, announced that study results presented today during the International Society for CNSClinical Trials
USING AN ARTIFICIAL INTELLIGENCE PLATFORM TO ACCURATELY Using an artificial intelligence platform to accurately predict pharmacokinetic sampling outcomes in clinical trials INTRODUCTION METHODS DATA AND RESULTS CONCLUSION AICURE – THE LINK BETWEEN PATIENTS, DISEASE AND TREATMENT.EVENTS & NEWSBLOGLEARNCOVID-19COMPANYCONTACT AiCure – The link between patients, disease and treatment. The Right Dose for. the Right Patient. AiCure delivers a compliant, scalable AI platform to maximize the impact of data on clinical research and end-to-end operations, from pre-clinical to commercialization. AiCure brings AI to the life sciences industry to guide data-driven decisionAICURE
AiCure Support +1(800) 770-1266 | support@aicure.com | Help CenterHelp Center
COMPANY – AICURE
Company. AiCure delivers patient insights to improve clinical trials. As the only company to provide a holistic view of the patient, AiCure directly engages patients via smartphones to deliver meaningful, high-quality data around patient behavior to sponsors and sites. These insights from AiCure’s proprietary AI platform empower sites toLEARN – AICURE
Collaborating with AiCure is a unique opportunity to bring deeper and more novel insights to clinical research without participants ever having to leave the comfort of home. The AiCure platform aligns with our unique product development model that harnesses behavioralOPENDBM – AICURE
AiCure’s OpenDBM is a software package that allows for calculation of digital biomarkers of health and functioning from video or audio of an individual’s behavior. It integrates existing tools for measurement of behavioral characteristics such as facial activity, voice, and movement into a single package for measurement of overallbehavior.
SITE-PERSPECTIVES ON PATIENT ENGAGEMENT: SOLUTIONS FOR Site-Perspectives on Patient Engagement: Solutions for NASH Trials. By Nadege Gunn, MD. Keeping track of patients in clinical trials has always been challenging for sites and sponsors. However, the COVID-19 pandemic has taken the challenge of patient engagement to new levels. Patients with fatty liver disorders such as nonalcoholic DEMYSTIFYING CNS SYMPTOM TRACKING WITH ADVANCED AI Tingling or numbness in the extremities. Weakness. Loss of sight or changes in sight. Memory loss. Changes to cognitive ability. Lack of coordination. These kinds of symptoms typically fluctuate in severity over time. They can also be impacted by factors outside the therapy being studied. For instance, the patient’s level of physicalactivity
USE OF DIGITAL BIOMARKERS IN A PARKINSON’S DISEASE OPEN Open-label extension study to test the safety and efficacy of CVL-751 Use of digital biomarkers in a Parkinson’s Disease open-label extension study for frequent and objective assessment of AICURE ANNOUNCES NEW STUDY RESULTS DEMONSTRATING 90% AiCure announces new study results demonstrating 90% adherence from Phase 2 Abbvie study. New York, Sept. 26, 2016 — AiCure, a clinically-validated artificial intelligence company that visually confirms medication ingestion on smartphones, announced that study results presented today during the International Society for CNSClinical Trials
USING AN ARTIFICIAL INTELLIGENCE PLATFORM TO ACCURATELY Using an artificial intelligence platform to accurately predict pharmacokinetic sampling outcomes in clinical trials INTRODUCTION METHODS DATA AND RESULTS CONCLUSIONNEWS – AICURE
The link between patients, disease and treatment. IMA Clinical Research, a division of The IMA Group, will equip patients with AiCure’s patient engagement solution to observePROMOTIONAL VIDEO
The link between patients, disease and treatment. Join our Newsletterfor latest updates
AIPEX™ PARTNERSHIPS AiPEX™ is a formal AiCure-CRO partnership, designed to provide higher quality data and robust insights for faster and smaller clinical trials. AiPEX™ partners gain a competitive advantage by leveraging AiCure’s platform of Medication Adherence and Predictive Insights, Digital Biomarkers, and ePRO products to understand safetyand efficacy
LET’S GET IN TOUCH AiCure Headquarters. 19 West, 24th street, 11th Floor New York, NY 10010 USA (800) 570-0448 info@aicure.com AICURE AND THE IMA GROUP PARTNER TO OPTIMIZE CLINICAL The link between patients, disease and treatment. Posted on March 15, 2021 1:00 PM AiCure and The IMA Group Partner to Optimize Clinical Trial Recruitment and Patient Engagement LET’S GET CLINICAL! Posted on. Feb 09 2021. One or Two Weeks of Dosing Data is All You Need for an Optimized Patient Pool. By Rich Christie, MD PhD. Postedon. Jan 26 2021.
BUILDING ON MOMENTUM: AICURE ANNOUNCES LEADERSHIP CHANGES Ed Ikeguchi, M.D. Named AiCure’s First President . Founder and Board member Adam Hanina Assumes Role as Head of Special Projects. NEW YORK, Jan. 28, 2020 – AiCure, recognized as one of the world’s 100 most innovative artificial intelligence companies, announced changes in leadership, including the creation of a new role of president, as part of a well-defined strategic planning PATIENT-CENTERED APPROACHES TO CLINICAL RESEARCH IN This is a tremendous benefit for oncology patients, who are often immunocompromised and may need to avoid clinical visits to prevent the risk of hospital-acquired infections or, of course, COVID-19. These remote capabilities include virtual visits, targeted questionnaires and electronic patient-reported outcome (ePRO) assessments, amongothers.
HOW AI CAN IMPROVE UNDERSTANDING OF PATIENT’S BEHAVIOR AND A positive patient experience can go a long way to improve data through better retention and dosing support. A patient who feels supported is more likely to remain engaged through the course of the trial. Technology can be extremely useful in helping patients to manage their study participation along with the litany of other life USING AI TO PROVIDE NEW INSIGHTS INTO INTENTIONAL DOSE NON Using AI to Provide New Insights into Intentional Dose Non-Adherence. By Ken Getz, MBA. Inadvertent and intentional dose non-adherence in clinical trials has been a major drug development challenge for decades. Studies in the literature have demonstrated that a high percentage of study volunteers — as high as 75% — conceal orfabricate
AICURE – THE LINK BETWEEN PATIENTS, DISEASE AND TREATMENT.EVENTS & NEWSBLOGLEARNCOVID-19COMPANYCONTACT AiCure – The link between patients, disease and treatment. The Right Dose for. the Right Patient. AiCure delivers a compliant, scalable AI platform to maximize the impact of data on clinical research and end-to-end operations, from pre-clinical to commercialization. AiCure brings AI to the life sciences industry to guide data-driven decisionAICURE
AiCure Support +1(800) 770-1266 | support@aicure.com | Help CenterHelp Center
COMPANY – AICURE
Company. AiCure delivers patient insights to improve clinical trials. As the only company to provide a holistic view of the patient, AiCure directly engages patients via smartphones to deliver meaningful, high-quality data around patient behavior to sponsors and sites. These insights from AiCure’s proprietary AI platform empower sites toLEARN – AICURE
Collaborating with AiCure is a unique opportunity to bring deeper and more novel insights to clinical research without participants ever having to leave the comfort of home. The AiCure platform aligns with our unique product development model that harnesses behavioral SITE-PERSPECTIVES ON PATIENT ENGAGEMENT: SOLUTIONS FOR Site-Perspectives on Patient Engagement: Solutions for NASH Trials. By Nadege Gunn, MD. Keeping track of patients in clinical trials has always been challenging for sites and sponsors. However, the COVID-19 pandemic has taken the challenge of patient engagement to new levels. Patients with fatty liver disorders such as nonalcoholicOPENDBM – AICURE
AiCure’s OpenDBM is a software package that allows for calculation of digital biomarkers of health and functioning from video or audio of an individual’s behavior. It integrates existing tools for measurement of behavioral characteristics such as facial activity, voice, and movement into a single package for measurement of overallbehavior.
WHAT’S NEXT POST-COVID-19: THE NEXT NORMAL The report, Beyond COVID-19: Pharma Reimagined, states that an overwhelming majority — 85.2% — of respondents anticipate higher levels of investment into digital over the next six to 12 months due to the pandemic, with many more — 82.8% — anticipating sustained investment over 24 months. DEMYSTIFYING CNS SYMPTOM TRACKING WITH ADVANCED AI Tingling or numbness in the extremities. Weakness. Loss of sight or changes in sight. Memory loss. Changes to cognitive ability. Lack of coordination. These kinds of symptoms typically fluctuate in severity over time. They can also be impacted by factors outside the therapy being studied. For instance, the patient’s level of physicalactivity
USE OF DIGITAL BIOMARKERS IN A PARKINSON’S DISEASE OPEN Open-label extension study to test the safety and efficacy of CVL-751 Use of digital biomarkers in a Parkinson’s Disease open-label extension study for frequent and objective assessment of AI CURE TECHNOLOGIES ADHERENCE SOLUTIONS REGISTERED WITH (New York, NY) – December 12, 2012 – Ai Cure’s suite of solutions, including AiView ®, AiView-SL TM and AiBreathe TM, has been registered with the FDA as a 510K class 1 exempt device.The patented facial recognition solutions allow for the monitoring and intervention with patients taking prescription medications in either tablet, sublingual or inhaler form. AICURE – THE LINK BETWEEN PATIENTS, DISEASE AND TREATMENT.EVENTS & NEWSBLOGLEARNCOVID-19COMPANYCONTACT AiCure – The link between patients, disease and treatment. The Right Dose for. the Right Patient. AiCure delivers a compliant, scalable AI platform to maximize the impact of data on clinical research and end-to-end operations, from pre-clinical to commercialization. AiCure brings AI to the life sciences industry to guide data-driven decisionAICURE
AiCure Support +1(800) 770-1266 | support@aicure.com | Help CenterHelp Center
COMPANY – AICURE
Company. AiCure delivers patient insights to improve clinical trials. As the only company to provide a holistic view of the patient, AiCure directly engages patients via smartphones to deliver meaningful, high-quality data around patient behavior to sponsors and sites. These insights from AiCure’s proprietary AI platform empower sites toLEARN – AICURE
Collaborating with AiCure is a unique opportunity to bring deeper and more novel insights to clinical research without participants ever having to leave the comfort of home. The AiCure platform aligns with our unique product development model that harnesses behavioral SITE-PERSPECTIVES ON PATIENT ENGAGEMENT: SOLUTIONS FOR Site-Perspectives on Patient Engagement: Solutions for NASH Trials. By Nadege Gunn, MD. Keeping track of patients in clinical trials has always been challenging for sites and sponsors. However, the COVID-19 pandemic has taken the challenge of patient engagement to new levels. Patients with fatty liver disorders such as nonalcoholicOPENDBM – AICURE
AiCure’s OpenDBM is a software package that allows for calculation of digital biomarkers of health and functioning from video or audio of an individual’s behavior. It integrates existing tools for measurement of behavioral characteristics such as facial activity, voice, and movement into a single package for measurement of overallbehavior.
WHAT’S NEXT POST-COVID-19: THE NEXT NORMAL The report, Beyond COVID-19: Pharma Reimagined, states that an overwhelming majority — 85.2% — of respondents anticipate higher levels of investment into digital over the next six to 12 months due to the pandemic, with many more — 82.8% — anticipating sustained investment over 24 months. DEMYSTIFYING CNS SYMPTOM TRACKING WITH ADVANCED AI Tingling or numbness in the extremities. Weakness. Loss of sight or changes in sight. Memory loss. Changes to cognitive ability. Lack of coordination. These kinds of symptoms typically fluctuate in severity over time. They can also be impacted by factors outside the therapy being studied. For instance, the patient’s level of physicalactivity
USE OF DIGITAL BIOMARKERS IN A PARKINSON’S DISEASE OPEN Open-label extension study to test the safety and efficacy of CVL-751 Use of digital biomarkers in a Parkinson’s Disease open-label extension study for frequent and objective assessment of AI CURE TECHNOLOGIES ADHERENCE SOLUTIONS REGISTERED WITH (New York, NY) – December 12, 2012 – Ai Cure’s suite of solutions, including AiView ®, AiView-SL TM and AiBreathe TM, has been registered with the FDA as a 510K class 1 exempt device.The patented facial recognition solutions allow for the monitoring and intervention with patients taking prescription medications in either tablet, sublingual or inhaler form.NEWS – AICURE
The link between patients, disease and treatment. IMA Clinical Research, a division of The IMA Group, will equip patients with AiCure’s patient engagement solution to observeEVENTS – AICURE
Join AiCure and uMotif’s live webcast, to hear from their panel representing sponsors, solution providers, and patients, to explore how. From. Apr 07 2021 -. to. Apr 09 2021.OPENDBM – AICURE
AiCure’s OpenDBM is a software package that allows for calculation of digital biomarkers of health and functioning from video or audio of an individual’s behavior. It integrates existing tools for measurement of behavioral characteristics such as facial activity, voice, and movement into a single package for measurement of overallbehavior.
CAREERS – AICURE
Manages all aspects of advancing qualified leads to booked business. Coordinates with other AiCure personnel involved in closing the opportunity including Operations, Product, Engineering, and Finance. Maintains a high-level of self-awareness and responsiveness to coaching. Owns self-development. LET’S GET IN TOUCH AiCure Headquarters. 19 West, 24th street, 11th Floor New York, NY 10010 USA (800) 570-0448 info@aicure.com AICURE AND THE IMA GROUP PARTNER TO OPTIMIZE CLINICAL The link between patients, disease and treatment. Posted on March 15, 2021 1:00 PM AiCure and The IMA Group Partner to Optimize Clinical Trial Recruitment and Patient Engagement LET’S GET CLINICAL! Posted on. Feb 09 2021. One or Two Weeks of Dosing Data is All You Need for an Optimized Patient Pool. By Rich Christie, MD PhD. Postedon. Jan 26 2021.
SCIENCE 37® AND AICURE PARTNER TO ENHANCE VIRTUAL CLINICAL The partnership combines artificial intelligence with comprehensive virtual trial services to bring novel insights to research. LOS ANGELES & NEW YORK, April 30, 2020 — Science 37, the industry leader in virtual clinical trials, and AiCure, a leading artificial intelligence (AI) and advanced data analytics company, have announced a collaboration to support and deliver enhanced technology for USING AI TO PROVIDE NEW INSIGHTS INTO INTENTIONAL DOSE NON Using AI to Provide New Insights into Intentional Dose Non-Adherence. By Ken Getz, MBA. Inadvertent and intentional dose non-adherence in clinical trials has been a major drug development challenge for decades. Studies in the literature have demonstrated that a high percentage of study volunteers — as high as 75% — conceal orfabricate
USING AN ARTIFICIAL INTELLIGENCE PLATFORM TO ACCURATELY Using an artificial intelligence platform to accurately predict pharmacokinetic sampling outcomes in clinical trials INTRODUCTION METHODS DATA AND RESULTS CONCLUSION AICURE – THE LINK BETWEEN PATIENTS, DISEASE AND TREATMENT.EVENTS & NEWSBLOGLEARNCOVID-19COMPANYCONTACT AiCure – The link between patients, disease and treatment. The Right Dose for. the Right Patient. AiCure delivers a compliant, scalable AI platform to maximize the impact of data on clinical research and end-to-end operations, from pre-clinical to commercialization. AiCure brings AI to the life sciences industry to guide data-driven decisionAICURE
AiCure Support +1(800) 770-1266 | support@aicure.com | Help CenterHelp Center
COMPANY – AICURE
Company. AiCure delivers patient insights to improve clinical trials. As the only company to provide a holistic view of the patient, AiCure directly engages patients via smartphones to deliver meaningful, high-quality data around patient behavior to sponsors and sites. These insights from AiCure’s proprietary AI platform empower sites toNEWS – AICURE
The link between patients, disease and treatment. IMA Clinical Research, a division of The IMA Group, will equip patients with AiCure’s patient engagement solution to observeLEARN – AICURE
Collaborating with AiCure is a unique opportunity to bring deeper and more novel insights to clinical research without participants ever having to leave the comfort of home. The AiCure platform aligns with our unique product development model that harnesses behavioral SITE-PERSPECTIVES ON PATIENT ENGAGEMENT: SOLUTIONS FOR Site-Perspectives on Patient Engagement: Solutions for NASH Trials. By Nadege Gunn, MD. Keeping track of patients in clinical trials has always been challenging for sites and sponsors. However, the COVID-19 pandemic has taken the challenge of patient engagement to new levels. Patients with fatty liver disorders such as nonalcoholicOPENDBM – AICURE
AiCure’s OpenDBM is a software package that allows for calculation of digital biomarkers of health and functioning from video or audio of an individual’s behavior. It integrates existing tools for measurement of behavioral characteristics such as facial activity, voice, and movement into a single package for measurement of overallbehavior.
DEMYSTIFYING CNS SYMPTOM TRACKING WITH ADVANCED AI Tingling or numbness in the extremities. Weakness. Loss of sight or changes in sight. Memory loss. Changes to cognitive ability. Lack of coordination. These kinds of symptoms typically fluctuate in severity over time. They can also be impacted by factors outside the therapy being studied. For instance, the patient’s level of physicalactivity
5 Q’S FOR ADAM HANINA, CEO OF AICURE 5 Q’s for Adam Hanina, CEO of AiCure. The Center for Data Innovation spoke with Adam Hanina, chief executive officer of AiCure, a healthcare software company based in New York City. Hanina discussed the value of public sector funding in innovation and how AI can help patients adhere to medication and treatment plans. USE OF DIGITAL BIOMARKERS IN A PARKINSON’S DISEASE OPEN Open-label extension study to test the safety and efficacy of CVL-751 Use of digital biomarkers in a Parkinson’s Disease open-label extension study for frequent and objective assessment of AICURE – THE LINK BETWEEN PATIENTS, DISEASE AND TREATMENT.EVENTS & NEWSBLOGLEARNCOVID-19COMPANYCONTACT AiCure – The link between patients, disease and treatment. The Right Dose for. the Right Patient. AiCure delivers a compliant, scalable AI platform to maximize the impact of data on clinical research and end-to-end operations, from pre-clinical to commercialization. AiCure brings AI to the life sciences industry to guide data-driven decisionAICURE
AiCure Support +1(800) 770-1266 | support@aicure.com | Help CenterHelp Center
COMPANY – AICURE
Company. AiCure delivers patient insights to improve clinical trials. As the only company to provide a holistic view of the patient, AiCure directly engages patients via smartphones to deliver meaningful, high-quality data around patient behavior to sponsors and sites. These insights from AiCure’s proprietary AI platform empower sites toNEWS – AICURE
The link between patients, disease and treatment. IMA Clinical Research, a division of The IMA Group, will equip patients with AiCure’s patient engagement solution to observeLEARN – AICURE
Collaborating with AiCure is a unique opportunity to bring deeper and more novel insights to clinical research without participants ever having to leave the comfort of home. The AiCure platform aligns with our unique product development model that harnesses behavioral SITE-PERSPECTIVES ON PATIENT ENGAGEMENT: SOLUTIONS FOR Site-Perspectives on Patient Engagement: Solutions for NASH Trials. By Nadege Gunn, MD. Keeping track of patients in clinical trials has always been challenging for sites and sponsors. However, the COVID-19 pandemic has taken the challenge of patient engagement to new levels. Patients with fatty liver disorders such as nonalcoholicOPENDBM – AICURE
AiCure’s OpenDBM is a software package that allows for calculation of digital biomarkers of health and functioning from video or audio of an individual’s behavior. It integrates existing tools for measurement of behavioral characteristics such as facial activity, voice, and movement into a single package for measurement of overallbehavior.
DEMYSTIFYING CNS SYMPTOM TRACKING WITH ADVANCED AI Tingling or numbness in the extremities. Weakness. Loss of sight or changes in sight. Memory loss. Changes to cognitive ability. Lack of coordination. These kinds of symptoms typically fluctuate in severity over time. They can also be impacted by factors outside the therapy being studied. For instance, the patient’s level of physicalactivity
5 Q’S FOR ADAM HANINA, CEO OF AICURE 5 Q’s for Adam Hanina, CEO of AiCure. The Center for Data Innovation spoke with Adam Hanina, chief executive officer of AiCure, a healthcare software company based in New York City. Hanina discussed the value of public sector funding in innovation and how AI can help patients adhere to medication and treatment plans. USE OF DIGITAL BIOMARKERS IN A PARKINSON’S DISEASE OPEN Open-label extension study to test the safety and efficacy of CVL-751 Use of digital biomarkers in a Parkinson’s Disease open-label extension study for frequent and objective assessment ofLEARN – AICURE
Collaborating with AiCure is a unique opportunity to bring deeper and more novel insights to clinical research without participants ever having to leave the comfort of home. The AiCure platform aligns with our unique product development model that harnesses behavioralOPENDBM – AICURE
AiCure’s OpenDBM is a software package that allows for calculation of digital biomarkers of health and functioning from video or audio of an individual’s behavior. It integrates existing tools for measurement of behavioral characteristics such as facial activity, voice, and movement into a single package for measurement of overallbehavior.
CAREERS – AICURE
Manages all aspects of advancing qualified leads to booked business. Coordinates with other AiCure personnel involved in closing the opportunity including Operations, Product, Engineering, and Finance. Maintains a high-level of self-awareness and responsiveness to coaching. Owns self-development.PROMOTIONAL VIDEO
The link between patients, disease and treatment. Join our Newsletterfor latest updates
LET’S GET CLINICAL! Posted on. Feb 09 2021. One or Two Weeks of Dosing Data is All You Need for an Optimized Patient Pool. By Rich Christie, MD PhD. Postedon. Jan 26 2021.
AICURE AND THE IMA GROUP PARTNER TO OPTIMIZE CLINICAL The link between patients, disease and treatment. Posted on March 15, 2021 1:00 PM AiCure and The IMA Group Partner to Optimize Clinical Trial Recruitment and Patient Engagement LET’S GET IN TOUCH AiCure Headquarters. 19 West, 24th street, 11th Floor New York, NY 10010 USA (800) 570-0448 info@aicure.com WHAT’S NEXT POST-COVID-19: THE NEXT NORMAL The report, Beyond COVID-19: Pharma Reimagined, states that an overwhelming majority — 85.2% — of respondents anticipate higher levels of investment into digital over the next six to 12 months due to the pandemic, with many more — 82.8% — anticipating sustained investment over 24 months. USING AI TO PROVIDE NEW INSIGHTS INTO INTENTIONAL DOSE NON Using AI to Provide New Insights into Intentional Dose Non-Adherence. By Ken Getz, MBA. Inadvertent and intentional dose non-adherence in clinical trials has been a major drug development challenge for decades. Studies in the literature have demonstrated that a high percentage of study volunteers — as high as 75% — conceal orfabricate
AI CURE TECHNOLOGIES ADHERENCE SOLUTIONS REGISTERED WITH (New York, NY) – December 12, 2012 – Ai Cure’s suite of solutions, including AiView ®, AiView-SL TM and AiBreathe TM, has been registered with the FDA as a 510K class 1 exempt device.The patented facial recognition solutions allow for the monitoring and intervention with patients taking prescription medications in either tablet, sublingual or inhaler form.Skip to content
* Events & News
* Blog
* Learn
* OpenDBM
* Partnerships
* Company
* Contact
__ __
PATIENT INSIGHTS. MEANINGFUL TRIALS AiCure uses an easy-to-use, proprietary AI platform to directly engage and provide support to patients via smartphones to deliver meaningful, high-quality data around patient behavior.FEATURES
PATIENT-FIRST
Real-time access to patient data helps inform safety and efficacyresults.
TRIAL FLEXIBILITY
Support for remote and virtual trials. CREATE BETTER ANALYSES Real-time patient data facilitates better decision-making. ACCELERATE TIMELINES Real-time access to insights enables data-driven decisions.LEARN MORE IMPROVE RESOURCE ALLOCATION Earlier decisions about study viability and resource allocations. OPTIMIZED SITE MANAGEMENT Maximize return on site-activation costs. AICURE PATIENT CONNECT™ By using AiCure Patient Connect, sponsors, sites and patients can access powerful data and maintain high engagement with an easy-to-use, patient-first mobile application. Our comprehensive computer-vision and AI platform enables sponsors to collect, curate, and annotate insights extracted with cutting-edge analytical tools, using sponsor in-house data teams or in collaboration with AiCure data scientists.Learn More
DOSING SUPPORT, ADHERENCE, AND INSIGHTS Using the front-facing camera of a phone, we visually confirm when each dose is taken or missed, all from the comfort of a patient’s home. An in-depth understanding of dosing behavior lets sponsors help patients maintain treatment regimens. Sites can connect with patients via chat, text, and video to strengthen relationships, understand the context of care, and better assess issues that might impact studyconduct. Learn More
FLEXIBILITY TO SUPPORT PATIENTS AND SITES IN ALL TRIAL CONFIGURATIONS, INCLUDING SITE-BASED, HYBRID AND VIRTUAL AiCure empowers sponsors and sites to implement the right trial for the right patient by providing a comprehensive understanding of the effectiveness of the drug while accelerating timelines, reducing trial costs, and limiting data variability.EPRO
Provide patients a quick and easy way to record patient-reported outcomes in the form of e-diaries and validated questionnaires. Our ePRO product quickly enables participants to record their symptoms in one easy-to-use integrated platform and documents responses on the same platform as dosing information. Learn MoreDIGITAL BIOMARKERS
Leverage computer vision and AI to gather and analyze visual and auditory cues directly through the patient’s smartphone. Pinpoint critical patient responses and behavioral trends. Scientifically-validated, remote assessment of patient response deepens the pool of clinical data available to interpret study findings and drive decision-making. Learn More LET US HELP YOU REDUCE RISK IN CLINICAL RESEARCH AND IMPROVE QUALITY OF CARE FOR YOUR PATIENTS: -- Select Inquiry Type* --PartnershipsProduct DemoPatient or Site in a Clinical TrialBusiness Development OpportunitiesCareer InquiriesAnalyst Inquiries* Home
* Contact
* Events & News
* Blog
* Learn
* OpenDBM
* Partnerships
* Careers
* Company
* __
* __
JOIN OUR NEWSLETTER FOR LATEST UPDATESE-mail address
2020 AiCure. All Rights Reserved. Terms of Use | Privacy Policy | EU-US & Swiss-US Privacy ShieldDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0